Cargando…
BRAF V600E-mutated metastatic pediatric Wilms tumor with complete response to targeted RAF/MEK inhibition
Wilms tumor (WT) is the most common renal malignancy of childhood and accounts for 6% of all childhood malignancies. With current therapies, the 5-yr overall survival (OS) for children with unilateral favorable histology WT is greater than 85%. The prognosis is worse, however, for the roughly 15% of...
Autores principales: | Obasaju, Patience, Shahab, Shubin, Dunn, Emily, Rhee, Daniel S., Jiang, LiQun, Dome, Jeffrey S., Friedman, Alan D., Argani, Pedram, Pratilas, Christine A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7133746/ https://www.ncbi.nlm.nih.gov/pubmed/32238401 http://dx.doi.org/10.1101/mcs.a004820 |
Ejemplares similares
-
BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
por: Schreck, Karisa C., et al.
Publicado: (2019) -
Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
por: Molnár, Eszter, et al.
Publicado: (2018) -
Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition
por: Allen, Amy, et al.
Publicado: (2019) -
BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021) -
BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
por: Saijo, Ken, et al.
Publicado: (2022)